Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin

Journal of Viral Hepatitis

Volumn 16, Issue 8, 2009, Pages 586-594

  Hiramatsu, N ^a   Oze, T ^a   Yakushijin, T ^a   Inoue, Y ^a   Igura, T ^a   Mochizuki, K ^a   Imanaka, K ^b   Kaneko, A ^c   Oshita, M ^c   Hagiwara, H ^d   Mita, E ^e   Nagase, T ^f   Ito, T ^g   Inui, Y ^h   Hijioka, T ⁱ   Katayama, K ^j   Tamura, S ^k   Yoshihara, H ^l   Imai, Y ^m   Kato, M ⁿ   Yoshida, Y ^a   Tatsumi, T ^a   Ohkawa, K ^a   Kiso, S ^a   Kanto, T ^a   Kasahara, A ^a   Takehara, T ^a   Hayashi, N ^a   more..

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c OSAKA POLICE HOSPITAL   (Japan)

^d Higashiosaka City General Hospital   (Japan)

^e OSAKA NATIONAL HOSPITAL   (Japan)

^f Suita Municipal Hospital   (Japan)

^g KANSAI ROSAI HOSPITAL   (Japan)

^h Hyogo Prefectural Nishinomiya Hospital   (Japan)

ⁱ MINAMI OSAKA GENERAL HOSPITAL   (Japan)

^j OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^k Minoh City Hospital   (Japan)

^l OSAKA ROSAI HOSPITAL   (Japan)

^m Ikeda Municipal Hospital   (Japan)

ⁿ National Hospital Organizaton Minami Wakayama Medical Center   (Japan)

more..

Author keywords

Chronic hepatitis C; Drug exposure; Pegylated interferon plus ribavirin; Virologic relapse

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; VIROLOGY;

AGED; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECURRENCE; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 68749109781     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01106.x     Document Type: Article

References (31)

1. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358 : 958 965.
2. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 982.
3. Hadziyannis SJ, Sette Jr. H, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 355.
4. Hayashi N, Takehara T. Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol 2006 41 : 17 27.
5. Zeuzem S, Hultcrantz R, Bourliere M et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004 40 : 993 999.
6. Ferenci P, Brunner H, Laferl H et al. A randomized, prospective trial of ribavirin 400 mg day-1 versus 800 mg day-1 in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3. Hepatology 2008 47 : 1816 1823.
7. McHutchison JG, Manns M, Patel K et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002 123 : 1061 1069.
8. Shiffman ML, Ghany MG, Morgan TR et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007 132 : 103 112.
9. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998 339 : 1485 1492.
10. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998 352 : 1426 1432.
11. Davis GL, Esteban-Mur R, Rustgi V et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998 339 : 1493 1499.
12. Lindsay KL, Trepo C, Heintges T et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001 34 : 395 403.
13. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003 38 : 645 652. (Pubitemid 37052151)
14. Shiffman ML, Di Bisceglie AM, Lindsay KL et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004 126 : 1015 1023.
15. Reddy KR, Shiffman ML, Morgan TR et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007 5 : 124 129.
16. Lodato F, Azzaroli F, Brillanti S et al. Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study. J Viral Hepat 2005 12 : 536 542.
17. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005 41 : 275 279.
18. Bronowicki JP, Ouzan D, Asselah T et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006 131 : 1040 1048. (Pubitemid 44515099)
19. Oze T, Hiramatsu N, Yakushijin T et al. Peginterferon alfa-2b affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with pegylated interferon alfa-2b plus ribavirin. J Viral Hepat, in press.
20. Berg T, von Wagner M, Nasser S et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006 130 : 1086 1097.
21. Sanchez-Tapias JM, Diago M, Escartin P et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006 131 : 451 460.
22. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 2007 46 (6 1688 1694.
23. Mangia A, Minerva N, Bacca D et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008 47 : 43 50.
24. Shiffman ML, Salvatore J, Hubbard S et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007 46 : 371 379.
25. Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003 37 : 1343 1350.
26. Jacobson IM, Brown RS Jr., McCone J et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology 2007 46 : 982 990.
27. Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991 337 : 1058 1061.
28. Di Bisceglie AM, Shindo M, Fong TL et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992 16 : 649 654.
29. Hiramatsu N, Hayashi N, Haruna Y et al. Immunohistochemical detection of hepatitis C virus-infected hepatocytes in chronic liver disease with monoclonal antibodies to core, envelope and NS3 regions of the hepatitis C virus genome. Hepatology 1992 16 : 306 311.
30. Miyatake H, Kanto T, Inoue M et al. Impaired ability of interferon-alpha-primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection. J Viral Hepat 2007 14 : 404 412.
31. Itose I, Kanto T, Inoue M et al. Involvement of dendritic cell frequency and function in virological relapse in pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C patients. J Med Virol 2007 79 : 511 521.